



EUROPEAN COMMISSION

24.6.2022

SEC(2022) 540

### **REGULATORY SCRUTINY BOARD OPINION**

Revision of list of pollutants affecting surface and groundwaters

{COM(2022) 540}

{SWD(2022) 540, 543}





Brussels,  
RSB

## **Opinion**

**Title: Impact assessment / Revision of list of pollutants affecting surface and groundwaters**

**Overall opinion: POSITIVE WITH RESERVATIONS**

### **(A) Policy context**

The sustainable management of the EU's surface water and groundwater bodies is regulated by three Directives. This legislation lists a number of polluting substances and their threshold values, also in combination, as well as monitoring and reporting arrangements for these substances. A recent fitness check of EU water legislation identified areas of improvement in relation to tackling chemical pollution.

This initiative aims to address the legal obligation to review the lists of water pollutants and their corresponding standards. At the same time, it follows up on the findings of the water fitness check regarding implementation shortcomings, aiming to improve the regulatory response to emerging environmental and health risks.

### **(B) Summary of findings**

**The Board notes the additional information provided in advance of the meeting and commitments to make changes to the report.**

**However, the report still contains significant shortcomings. The Board gives a positive opinion with reservations because it expects the DG to rectify the following aspects:**

- (1) The design of the options is overly complex and does not bring out clearly the key policy choices.**
- (2) The impacts on SMEs and on citizens are not analysed sufficiently. The report does not assess how individual Member States may be affected.**
- (3) The report is not clear about the order of magnitude of the expected impacts. It does not critically assess the validity of the illustrative benefit and cost estimates and their relevance to this initiative. The comparison of options is not based on their effectiveness, efficiency and coherence.**

---

This opinion concerns a draft impact assessment which may differ from the final version.

### **(C) What to improve**

(1) The design of options should allow the identification of impacts, separately for each option or their combination. The options and their presentation should be simplified, and purely technical elements moved to the Annexes. The report should provide more aggregated and more relevant options and sub-options. Options linked to administrative simplification and burden reduction should be grouped together.

(2) The analysis of the impacts on SMEs and citizens should be further developed. The report should elaborate on the impacts on SMEs, including in terms of the compliance costs and administrative burden, and present the results of the application of the proportionate SME test. The impacts on consumers should also be further analysed (indicatively, in relation to pharmaceuticals, personal care products, consumers' health, cost of water services) and the evidence should be clearly presented for the conclusions reached. The report should be more explicit on the implementation deficits in the problem analysis and examine the different possible impacts across Member States. It should map out the respective efforts required from different Member States to meet the targets set.

(3) The report should critically examine the validity of the benefit and cost estimates presented as the examples of the potential impacts, provide more detail on the scope and methods used and indicate how relevant the examples are to this initiative. It should strengthen a summary of the results of the cost benefit analysis, taking into account all qualitative and quantitative evidence and indicating the overall order of magnitude of the expected impacts of the preferred option. Given the link with many existing and ongoing initiatives, the report should discuss the relevance and attribution of costs and benefits to this initiative. Annex 3 should be simplified to integrate in a concise manner the qualitative and quantitative evidence. The analysis should reflect any changes to the options' structure.

(4) The report should clarify the costs and cost savings in scope of the One In, One Out approach. The dedicated section and Annex 3 seem incomplete. All costs and benefits related to the One In, One Out approach should be identified and clearly presented.

(5) The report should systematically integrate the criteria of effectiveness, efficiency and coherence in the comparison of options.

The Board notes the estimated costs and benefits of the preferred option in this initiative, as summarised in the attached quantification tables.

*Some more technical comments have been sent directly to the author DG.*

### **(D) Conclusion**

**The DG must revise the report in accordance with the Board's findings before launching the interservice consultation.**

**If there are any changes in the choice or design of the preferred option in the final version of the report, the DG may need to further adjust the attached quantification tables to reflect this.**

Full title	Revision of the lists of pollutants affecting surface and groundwaters and the corresponding regulatory standards in the Environmental Quality Standards, Groundwater and Water Framework Directives
------------	--

Reference number	PLAN/2020/8554
Submitted to RSB on	25 May 2022
Date of RSB meeting	22 June 2022

## **ANNEX: Quantification tables extracted from the draft impact assessment report**

*The following tables contain information on the costs and benefits of the initiative on which the Board has given its opinion, as presented above.*

*If the draft report has been revised in line with the Board's recommendations, the content of these tables may be different from those in the final version of the impact assessment report, as published by the Commission.*

I. Overview of Benefits (total for all provisions) – Preferred Option		
Description	Amount	Comments
<b>Direct benefits</b>		
<b>Improved surface water quality</b>	<p><b>Additions:</b> total benefits not quantified for EU27, but:</p> <ul style="list-style-type: none"><li>- Avoided/reduced environmental impacts and potential toxic effects on aquatic species. E.g. Carbamazepine has population effects for aquatic species through impacts on fertility and reproduction (particularly crustaceans). Ibuprofen exhibits potential toxic effects for some aquatic species including fertility effects (hormone levels) in fish while nicosulfuron has aquatic toxicity (particularly to flora) and concerns over carcinogenicity as a secondary poisoning issue. Diclofenac is one of the highest concern pharmaceuticals for environmental impacts with potential toxic effects on avian populations via surface water species. Estrone E1, 17- Beta estradiol (E2), Ethinyl estradiol (EE2) are associated with chronic ecosystem level impacts from exposure to hormones and EDC. PFAS has a widespread and very long-lasting environmental effects while Bisphenol A causes population level effects as an endocrine disrupting chemical for aquatic organisms. Triclosan is toxic for aquatic organisms particularly larvae and fish eggs with effects identified on a range of aquatic species including amphibians. Acetamiprid, Clothianidin, Imidacloprid, Thiacloprid, Thiamethoxam Bifenthrin, Deltamethrin Esfenvalerate and Permethrin are associated with toxic aquatic effects against invertebrates, arthropods, and crustaceans with wider environmental concerns for terrestrial pollinators (with Bifenthrin, Deltamethrin Esfenvalerate, Permethrin being highly toxic to the aquatic environment even at low concentrations). Glyphosate is associated with potential harm to aquatic environments given the very high usage rates and risks for loss to water, including non-target aquatic flora.</li><li>- Avoided/reduced human health impacts (Glyphosate, Triclosan, PFAS, Bisphenol A via reduced exposure through drinking water) including from specific exposure to Neonicotinoids (Acetamiprid, Clothianidin, Imidacloprid, Thiacloprid, Thiamethoxam), EDC (Bifenthrin, Deltamethrin Esfenvalerate, Permethrin) and (potential) carcinogenic effects (Ethinyl estradiol (EE2), Nicosulfuron). E.g. Annual costs related to endocrine disruptors exposure were estimated to be €163 billion (above €22 billion with a 95% probability and above €196 billion with a 25% probability) (59). This is due to the fact that endocrine disruptors in Europe contribute substantially to neurobehavioral deficits and disease, with a high probability of &gt;€150 billion costs annually (69) as well as childhood obesity which costs €1.54 billion annually. Protection against AMR has clear societal benefits and avoided costs to healthcare from protections against the development of AMR within health settings (Azithromycin, Clarithromycin, Erythromycin). E.g. it is estimated that AMR costs the EU €1.5 billion per year in healthcare costs and productivity losses<sup>1</sup> (47) (70) (71).</li><li>- Avoided/reduced impacts on pollinators and agriculture (Acetamiprid, Clothianidin, Imidacloprid, Thiacloprid, Thiamethoxam, Bifenthrin, Deltamethrin</li></ul>	

<sup>1</sup> Based on an exchange rate of 1 EUR = 1.09 USD

This opinion concerns a draft impact assessment which may differ from the final version.

I. Overview of Benefits (total for all provisions) – Preferred Option		
Description	Amount	Comments
	<p>Esfenvalerate, Permethrin). E.g. across Europe, crop pollination by insects accounted for approximately €14.6 billion annually (72).</p> <ul style="list-style-type: none"> <li>- Avoided costs of water treatment for drinking water, agriculture and industry (Acetamiprid, Clothianidin, Imidacloprid, Thiacloprid, Thiamethoxam Bifenthrin, Deltamethrin Esfenvalerate, Permethrin, glyphosate, triclosan, bisphenol A, PFAS) (in the case of source control and pathway disruption measures). E.g. in 2015, approximately €0.5 billion was spent annually to remove pesticides in wastewater treatment plants (WWTP) in Europe (73).</li> <li>- Economic benefits for aquaculture from improved food quality (Estrone E1, 17- Beta estradiol (E2), Ethinyl estradiol (EE2), Acetamiprid, Clothianidin, Imidacloprid, Thiacloprid, Thiamethoxam Bifenthrin, Deltamethrin Esfenvalerate, Permethrin, Diclofenac, Carbamazepine, ibuprofen, Nicosulfuron, triclosan, PFAS, bisphenol A)</li> <li>- Innovation for development of alternative chemicals and technologies (e.g. Bisphenol A)</li> </ul>	
	<p><b>Amendments:</b> total benefits not quantified for EU27, but:</p> <ul style="list-style-type: none"> <li>- Updated EQS based on new science and re-appraisal of risk would provide more appropriate protections (all substances)</li> <li>- Improved protections for human health particularly in relation of POP substances, issues around bioaccumulation (dioxins and furans, chlorpyrifos, hexachlorobutadiene, HBCDD), EDC (diuron, chlorpyrifos), exposure to chronic pollutants (mercury, nickel). E.g. chlorpyrifos and PBDE as endocrine disruptors were associated with attention deficit hyperactivity disorder (ADHD) and with other cognitive deficiencies. The productivity loss caused by these disorders is estimated to be €124 billion annually in EU. Additionally, prenatal exposure to chlorpyrifos across the EU would cost an additional €21.4 billion in social costs. The neurotoxicity of chlorpyrifos is estimated to be 70 to 100% according to the epidemiological and toxicological evidence, which corresponds to a social cost of €46.8 billion and €195 billion annually in the EU (69). It was also estimated that the cognitive deficits caused by chlorpyrifos and methylmercury would cost the EU €177 billion and €9.89 billion, respectively</li> <li>- Reduced environmental concentrations, improved environmental protections for ecosystem services (cypermethrin, nonylphenols, PAHs)</li> <li>- Avoided health costs for aquaculture (cypermethrin, tributyltin, mercury, nickel)</li> <li>- Cost savings and efficiencies: the proposed EQS is less stringent for heptachlor/heptachlor oxide, hexachlorobenzene, PBDEs and fluoranthene, meaning resources can be reallocated and costs saved from measures no longer needed.</li> <li>- Potential innovation opportunity to remove use as an intermediate in manufacture of rubber products (diuron)</li> </ul>	
	<p><b>Other eight pollutants:</b> total benefits not quantified for EU27, but:</p> <ul style="list-style-type: none"> <li>- Three of the four cyclodiene pesticides (aldrin, dieldrin, endrin, isodrin is an isomer of aldrin) are listed as POPs under the Stockholm Convention and have been banned in the EU for many years. The rate of EQS exceedance suggests environmental risk is low, and benefits of continued monitoring may be limited. However, monitoring data are needed anyway under the POPs Regulation and could inform decontamination measures.</li> <li>- DDT is also a recognised POP. Use in EU has long since ceased and rate of EQS exceedance is extremely low. Maintaining the monitoring time-series would support the tracking of DDT in the environment, and link with monitoring of, e.g. imported foods.</li> <li>- While tetrachloroethylene and trichloroethylene are still in use, and health concerns well founded, the monitoring data shows exceedances in only 6 and 3 surface water bodies out of 97,000 suggesting a very low environmental risk at present. However, these substances are still of concern in groundwater and drinking water, and in marine waters, and the links between surface and groundwater bodies mean that for the moment it is prudent to continue monitoring them in surface waters.</li> </ul>	
	<p><b>Deselection:</b> total benefits not quantified for EU27, but</p> <ul style="list-style-type: none"> <li>• Deselection of substances that no longer represent an EU-wide risk could free up resources for reallocation by Competent Authorities to the monitoring and/or management of emerging pollutants, including watch-list substances and the new priority substances.</li> <li>• The pesticides alachlor, simazine and chlorfenvinphos are clearly hazardous but no longer approved for use; the risk of exposure is very low and would be expected to remain so.</li> <li>• Carbon tetrachloride and trichlorobenzenes are still in use. However, the rate of exceedance of the EQS is very low. Deselection of trichlorobenzenes is questionable compared to other substances given that its risk quotient RQ and MSFD relevance.</li> </ul>	

I. Overview of Benefits (total for all provisions) – Preferred Option		
Description	Amount	Comments
Improved groundwater quality	<p><b>PFAS:</b> total benefits not quantified for EU27, but</p> <ul style="list-style-type: none"> <li>• Lower risk of (irreversible) damage to natural resources such as groundwater and connected surface waters and ecosystems (i.e. reduced impact on sensitive water bodies such as wetlands and rivers, and fish);</li> <li>• Avoided illness / death through low level exposure through drinking water / food to PFAS: estimated the annual health expenditure due to kidney cancer €12.7 to €41.4 million in the EEA countries; hypertension in the EEA countries estimated at €10.7 to 35 billion per year (based on 207.8 million population);</li> <li>• Improved availability of clean raw groundwater for abstraction and lower production and maintenance costs (for drinking water, irrigation, livestock watering)</li> <li>• Benefits to sectors requiring a high quality of groundwater such as bottled water and other water uses (angling, swimming, etc).</li> <li>• Avoided costs of (pre)treatment as a result of improved quality for potable water and process water for drinking water supply, agriculture and industry (GAC treatment costs € millions per site) in the case of source control and pathway disruption measures</li> <li>• Reduced energy costs and related process costs for wastewater treatment to tackle PFAS (in the case of source control and pathway disruption measures)</li> <li>• Increased knowledge and understanding of the risks of PFAS posed to the water environment.</li> <li>• Consistent approach to data collection at EU level and improved knowledge (more data collected) on the impact of PFAS.</li> </ul> <p><b>Pharmaceuticals:</b> total benefits not quantified for EU27, but</p> <ul style="list-style-type: none"> <li>• Reduced pollution of groundwater and connected aquatic ecosystems with reduced impact on sensitive habitats.</li> <li>• Increased reuse and recovery of pharmaceutical-free materials (e.g. use of sludge, treated wastewater).</li> <li>• Reduction in AMR likely to be small (mainly covered by baseline measures) - Reduction in AMR through control of anti-biotic use (costs avoided of €1.5 billion to the EU)</li> <li>• Small increase in well-being from reduced risk of chronic ingestion in drinking water / improved ecosystem health.</li> <li>• Positive impact on shellfish and fisheries where groundwater inputs to rivers and estuaries is significant</li> <li>• Reduced energy, carbon emissions and chemicals use associated with reduced treatment of drinking water (in the case of source control and pathway disruption measures)</li> <li>• Improved efficiency - specific risks to groundwater are investigated and dealt with locally rather than through EU wide schemes which may be too high level to be effective</li> <li>• Consistent approach to data collection at EU level and improved knowledge (more data collected) on the impact of these two pharmaceuticals.</li> </ul> <p><b>nrMs:</b> total benefits not quantified for EU27, but</p> <ul style="list-style-type: none"> <li>• Reduced risk of damage to natural resources such as groundwater and connected ecosystems</li> <li>• Benefits to sectors requiring a high quality of groundwater such as bottled water or aquaculture and other water uses (angling, swimming, etc.).</li> <li>• Increased availability of clean raw groundwater for abstraction (for drinking water, irrigation, livestock watering)</li> <li>• Avoided costs of (pre)treatment as a result of improved quality for potable water and process water for agriculture and industry</li> <li>• Increased ecosystems services from groundwater biota not impacted by nrMs and cocktail effects</li> <li>• Climate change impacts through reduced energy use (e.g. due to changes to wastewater and drinking water treatment processes) (in the case of source control and pathway disruption measures).</li> <li>• Increased knowledge and understanding of the risks of metabolites of pesticides posed to the water environment.</li> <li>• plus reduced impacts on groundwater biota</li> </ul>	



I. Overview of Benefits (total for all provisions) – Preferred Option		
Description	Amount	Comments
	<ul style="list-style-type: none"> <li>Consistent approach to data collection at EU level and improved knowledge (more data collected) on nrMs in groundwater leading to better understanding of risks.</li> <li>Improved knowledge and better data for use during pesticide parent authorisation process.</li> </ul>	
<b>Indirect benefits</b>		
Digitalisation, administrative streamlining and better risk management options	<p>Option 2 (<b>Guidelines on the monitoring of groups/mixtures of pollutants</b>): not quantified for EU27, but the guidance document itself has limited impact, however a provision for monitoring estrogens with EBM could have substantial positive impacts.</p> <p>Option 6 (<b>An obligatory groundwater watchlist</b>): not quantified for EU27, but positive impacts due to better decision-making processes regarding substances posing risks and better comparability of data.</p> <p>Option 8 (<b>Repository of standards of EQSs for the RBSPs</b>): not quantified for EU27, but positive impact through harmonization of EU-wide standards allowing more effective measures. Positive impacts for social well-being and health, providing equal standard of water resource across EU</p> <p>Option 9 (<b>Allowing flexible adaptation to scientific progress and knowledge by updating the lists of pollutants and their EQS (under both SWD and GWD) by way of delegated acts</b>): not quantified for EU27, but positive impact due to quicker actions to address new substances. Positive impacts as innovation and research will lead to possible employment opportunities</p>	
<b>Administrative cost savings related to the 'one in, one out' approach*</b>		
(direct/indirect)	<p><u>Deselection of existing PS</u>: €3.8 million - €11.7 million per year (monitoring of 5 substances).</p> <p>The deselection of substances is likely to bring cost savings from no longer needing to monitor the deselected substances.</p>	

II. Overview of costs – Preferred option							
Cost type		Citizens / Consumers		Businesses		Administrations	
		One-off	Recurrent	One-off	Recurrent	One-off	Recurrent
Surface water	Direct adjustment costs	Not applicable - €0	Not applicable - €0	Additions: Not quantified for EU27, but:		Not quantified	Not quantified
				Significant costs to ensure compliance with proposed EQS for Ethinyl estradiol (EE2), Ibuprofen, Clothianidin, Imidacloprid, Thiamethoxam, Bifenthrin, Deltamethrin, Esfenvalerate, Permethrin, Glyphosate, Triclosan, PFAS and Bisphenol A implementing a range of source control, pathway disruption, targeted end of pipe treatment measures. E.g. the cost of a take-back scheme for unused pharmaceuticals in France is €10 million. The 2022 Annex XV restriction report for the proposed restriction of PFASs in firefighting foams estimates that the ban is estimated to cost society €6.8 billion over a 30-year period or €390 million per year (22). Costs of pathway disruption measures (e.g. buffer strips) is €472 million per			

II. Overview of costs – Preferred option							
Cost type		Citizens / Consumers		Businesses		Administrations	
		One-off	Recurrent	One-off	Recurrent	One-off	Recurrent
				year for pharmaceuticals; for pesticides these range from €162 million for clothianidin and imidacloprid to €285 million for glyphosate. Wastewater treatment range is €10- €32 per population equivalent, per annum (technology dependent).  <b>Moderate/Small costs</b> to ensure compliance for Estrone E1, 17- Beta estradiol (E2), Diclofenac, Carbamazepine, Azithromycin, Clarithromycin, Erythromycin, Acetamiprid, Thiachloprid, Nicosulfuron due to small distance to target, availability of source control and pathway disruption measures and/or positive impact of forthcoming revision of the UWWTD on quaternary end of pipe treatment. E.g. costs of pathway disruption measures (e.g. buffer strips) for pesticides range from €1.6 million for acetamiprid to €12.8 million for nicosulfuron. Wastewater treatment cost range is €10- €20 per population equivalent, per annum (technology dependent).  <u><b>Amendments:</b></u> Not quantified for EU27, but:  <b>Significant costs</b> to ensure compliance for Cypermethrin, Chlorpyrifos, Diuron, PAHs, Mercury, Nickel implementing a range of source control, pathway disruption, targeted end of pipe treatment measures. E.g. the restriction proposal which would ensure that granules or mulches (in particular from end-of-life tyres) are not placed on the market for use or used as infill material in synthetic turf pitches or similar applications if they contain more than 20 mg/kg in total of the eight indicator-PAHs would cost €45m (74) over a 10-year period. Costs of additional controls and treatment for farmed animal use of cypermethrin are €27.6 m². Wastewater treatment (Mercury, Nickel, PAH, Cypermethrin) - €1.17- €26.2 per population equivalent, per annum (technology dependent). Mine drainage (Mercury) - €100,000 -€10,000,000 per plant and €0.4 per dm³ operating costs.  <b>Moderate/Small costs</b> to ensure compliance for Dioxins and furans, Hexachlorobutadiene, Nonyl Phenol, Tributyltin due to small distance to target and/or limited scope for additional measures (likely to be natural attenuation and baseline end of pipe treatment (under the revised UWWTD)). E.g. the costs of			

<sup>2</sup> Cost calculation is based on the average cost of dip pens and containment areas to allow drying €1,120 as a one-off cost multiplied by the number of sheep farms in Eurostat (24,600) rounded to three significant figures.

II. Overview of costs – Preferred option							
Cost type		Citizens / Consumers		Businesses		Administrations	
		One-off	Recurrent	One-off	Recurrent	One-off	Recurrent
				restricting nonylphenol (NP) and its ethoxylates (NPE) in textiles was estimated to cost the EU €3.2m per annum for a reduction of 15 tonnes of NP/NPE released to surface water (74).  <b>No additional costs</b> for Dicofol, Heptachlor/ Heptachlor oxide, Hexachlorobenzene, Fluoranthene, PBDEs.  <u>Other 8 pollutants</u> : Not quantified, but minor additional compliance costs (extremely low current exceedances).			
<b>Surface water</b>	Direct administrative costs	Not applicable - €0	Not applicable - €0	Not quantified	Not quantified	Not quantified	Not quantified
<b>Surface water</b>	Direct regulatory fees and charges	Not applicable - €0	Not applicable - €0	Not quantified	Not quantified	Not applicable - €0	Not applicable - €0
<b>Surface water</b>	Direct enforcement costs	Not applicable - €0	Not applicable - €0	Not quantified	Not quantified	Not quantified	<b>Additions:</b> Not quantified for EU27 but additional analytical costs range from €11-100 per sample for all substances except for PFAS. For PFAS analytical costs are up to €250 per sample.  <b>Amendments:</b> Not quantified, but amendments for Chlorpyrifos and Dioxins and furans could lead to additional analytical costs (due to the proposed EQS being considerably lower than the existing one)

II. Overview of costs – Preferred option							
Cost type		Citizens / Consumers		Businesses		Administrations	
		One-off	Recurrent	One-off	Recurrent	One-off	Recurrent
							Other 8 pollutants: Not quantified, but cyclodiene pesticides, DDT, tetrachloroethylene and trichloroethylene have an EQS that warrants monitoring and analysis by MS.
Surface water	Indirect costs	<u>Additions:</u> Not quantified but additions of new substances could lead to: Possible societal impacts from loss of use (contraceptive pill, HRT, hormone treatments if Ethinyl estradiol (EE2) is restricted/banned Societal impacts from loss of use /restricted use of Diclofenac, Carbamazepine, Ibuprofen if controls implemented and increased costs for other types of medicine (including prescription only medications) Possible food security issues if loss of use without chemical/non-chemical alternatives in place (Bifenthrin, Deltamethrin, Esfenvalerate, Permethrin) Societal impacts for domestic pet owners if use of Imidacoprid is restricted Increased prices of goods and services as a result of source control measures.		Not quantified	Not quantified	Not applicable - €0	Not applicable - €0
Groundwater	Direct adjustment	Not applicable - €0	Not applicable - €0	<b>PFAS:</b> Not quantified for EU27, but: Restriction of use: €6.8 billion over a 30-year period or €390 million per year (22)		<b>PFAS:</b> Not quantified for	Not quantified

II. Overview of costs – Preferred option							
Cost type		Citizens / Consumers		Businesses		Administrations	
		One-off	Recurrent	One-off	Recurrent	One-off	Recurrent
	costs			per substitute use. Management of / contaminated biosolids (water industry): €201 million/yr (landfilling) to €503-€755 million/yr high temperature incineration of 10% of all biosolids Paper manufacturing: €77 million/yr (landfilling) to €192 -€288 million/yr high temperature incineration of paper mill wastes  <b>Pharmaceuticals:</b> Not quantified for EU27, but: Returns program / Green Pharmacy initiatives in a small number of MS (<€1-10 million per MS)  <b>nrMs:</b> Not quantified for EU27, but: Costs to pesticide sector through loss of approved substances, costs of product development and product substitution to the farming sector.		EU27, but: Contaminated soil remediation: €5 million (10 sites) - €760 million (20 sites) Cost of legacy pollution from landfill sites – average of €690,000 up to €77 million per site	
<b>Groundwater</b>	Direct administrative costs	Not applicable - €0	Not applicable - €0	Not quantified	Not quantified	Not quantified	Not quantified but no significant additional costs for risk / status assessments
	Direct regulatory fees and charges	Not applicable - €0	Not applicable - €0	Not quantified	Not quantified	Not applicable - €0	Not applicable - €0
	Direct enforcement costs	Not applicable - €0	Not applicable - €0	Not quantified	Not quantified	Not quantified	Additional analytical costs for EU27: PFAS: €45-48 million Pharma: €2 million nrMs: €4-5 million
	Indirect costs	Not quantified but proposals could lead to: - Possible societal impacts from loss of use of pharmaceuticals - Restricting use could impact on health and well-being of people and animals where alternatives have side effects / different efficacy.		Not quantified but proposals could lead to: <b>Pharmaceuticals:</b> - additional costs associated with substitution of pharmaceuticals and availability of alternatives (product substitution viable for Sulfathemoxazole but unlikely for Carbamazepine) <b>nrMs:</b> - Restrictions on use impact on farming sector and crop yields. Substitute pesticides are available and can be cheaper or up to 100 times more costly than permitted parent pesticides - Un-intentional impacts for example glyphosate is used to destroy cover crops, which are used to mitigate nutrients in run-off / leaching from		Not applicable - €0	Not applicable - €0

II. Overview of costs – Preferred option							
Cost type		Citizens / Consumers		Businesses		Administrations	
		One-off	Recurrent	One-off	Recurrent	One-off	Recurrent
				agricultural fields over winter - Increased data requirements could make gaining authorisation of new products more challenging.			
<b>Digitalisation, administrative streamlining and better risk management options</b>	Direct adjustment costs	Not applicable - €0	Not applicable - €0	Not quantified for EU27, but:  Option 2 (Guidelines on the monitoring of groups/ mixtures of pollutants): Costs due to monitoring of estrogen are low, but possible measure to be taken due to monitoring results may be substantial.  Option 8 (Repository of standards of EQSs for the RBSPs): agreeing on RBSPs EQSs would likely lead to substantial costs for MS for implementation of substantive measures where necessary.  Option 9 (Allowing flexible adaptation to scientific progress and knowledge by updating the lists of pollutants and their EQS (under both SWD and GWD) by way of delegated acts		Not quantified for EU27, but:  Option 2 (Guidelines on the monitoring of groups/mixtures of pollutants): Limited cost to develop the guidance document.	Not quantified for EU27, but:  Option 6 (An obligatory groundwater watchlist): Additional cost for monitoring and reporting
<b>Digitalisation, administrative streamlining and better risk management options</b>	Direct administrative costs	Not applicable - €0	Not applicable - €0			Not quantified	Not quantified
	Direct regulatory fees and charges	Not applicable - €0	Not applicable - €0	Not quantified	Not quantified	NA	NA
	Direct enforcement costs	Not applicable - €0	Not applicable - €0	Not quantified	Not quantified	Mon	Not quantified for EU27, but:  Option 2 (Guidelines on the monitoring of groups/ mixtures of pollutants): Minor monitoring costs of estrogens.  Option 6 (An obligatory groundwater watchlist): Additional cost for monitoring and reporting

II. Overview of costs – Preferred option							
Cost type		Citizens / Consumers		Businesses		Administrations	
		One-off	Recurrent	One-off	Recurrent	One-off	Recurrent
							Option 8 (Repository of standards of EQSs for the RBSPs): substantial costs for MS for implementation of monitoring (following the agreement on RBSPs EQSs)
	Indirect costs	Substitution Prices				NA	NA
<i>Costs related to the 'one in, one out' approach</i>							
<b>Total</b>	Direct adjustment costs	NA	NA	NA	NA	NA	NA
	Indirect adjustment costs	NA	NA	NA	NA	NA	NA
	Administrative costs (for offsetting)	NA	NA	NA	NA	NA	NA